Iotim

Quick links to important sections

Iotim

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Iotim

Property Description
Active ingredient Timolol maleate
Form Ophthalmic solution (Eye drop)
Pharmacological class Non-selective Beta-blocker
Common use Managing elevated eye pressure (IOP)
Origin Synthetic (Propanolamine Derivative)

Defining Iotim: Classification and Core Active Ingredient

Iotim is a specific prescription-only medicine (POM) recognized as a hypotensive ophthalmic glaucoma agent, utilized for the management of high fluid pressure within the eye. Its identity is centered on the active ingredient, Timolol maleate, a synthetic compound classified as a non-selective beta-adrenergic receptor blocking agent, widely known as a beta-blocker. Timolol has been utilized for several decades in reducing intraocular pressure, as a therapeutic option adapted for both adult and pediatric patient populations.

Composition and Physical Form of Iotim

Iotim is formulated as a sterile, buffered ophthalmic solution, routinely referred to as an eye drop, designed for topical administration onto the eye's surface. This preparation utilizes an aqueous solution as its primary vehicle, distinguishing it from gel-based ophthalmic preparations which have different viscosity properties. While the core Iotim product is a single-entity product for monotherapy, the key ingredient Timolol is also a component in various combination products intended to support multi-drug pressure regimens.

General Purpose: How Iotim Helps Maintain Eye Health

The essential general purpose of Iotim is to provide sustained control over elevated intraocular pressure (IOP), serving as a measure for long-term preservation of vision. The medication achieves this by exerting its principal action: reducing the production of the aqueous humor, the fluid constantly generated inside the eyeball. This mechanism is associated with substantial reductions in IOP. Maintaining stable, lower eye pressure helps to decrease the physical risk factor for potential, progressive damage to the patient’s optic nerve.

Regulatory References

  1. Timolol Ophthalmic: MedlinePlus Drug Information

What side effects are possible with Iotim?

Possible Side Effects and Safety Information

Iotim (Timolol Ophthalmic Solution) has an officially documented safety profile that includes both localized ocular reactions and potential systemic effects consistent with its classification as a non-selective beta-blocker. Due to systemic absorption, adverse reactions documented for oral beta-blocking agents may occur.


Adverse Reaction Classification

Adverse reactions are formally categorized by frequency in regulatory documents:

  • Common: Reactions occurring in 1% to 10% of patients, primarily involve the eye, such as blurred vision, burning, stinging, eye irritation, and conjunctival redness.
  • Uncommon/Rare: Less frequent reactions include systemic effects such as bradycardia (slow heart rate), headache, dizziness, syncope, and dry mouth. More rare reactions include severe cardiac or cerebrovascular events.

These effects are organized across various System-Organ Classes, including Ocular Disorders, Cardiac Disorders, Nervous System Disorders, and Respiratory Disorders.


Serious Safety Considerations and Restrictions

Regulatory documents highlight serious adverse reactions and specific patient restrictions. Fatalities due to severe bronchospasm have been reported, particularly in patients with pre-existing asthma, and occurrences of cardiac failure or cardiac arrest are also documented.

Iotim is formally contraindicated in patients with conditions like bronchial asthma, severe chronic obstructive pulmonary disease (COPD), sinus bradycardia, second- or third-degree atrioventricular block, or overt cardiac failure. For patients with diabetes, Timolol may mask the physical signs of acute hypoglycemia. Safety statements also note that following filtration surgery, choroidal detachment has been reported with aqueous suppressant therapy.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — official regulatory information for Iotim

Overdose Scope

Field Content
Documented overdose presentations Systemic manifestations, resulting from absorption of the beta-blocker, primarily include pronounced bradycardia (slow heart rate), hypotension (low blood pressure), and bronchospasm. Other signs include cardiac arrhythmias, dizziness, syncope, and headache.
Physiological systems affected (as stated in label) Cardiovascular system, Respiratory system, and Central Nervous System are the major organ systems affected.
Dose-related or exposure-related factors (if applicable) Overdose effects are related to the systemic absorption of Timolol maleate, which can occur even with topical ophthalmic use.
Population-specific overdose notes (if applicable) The risk of severe systemic effects is heightened in pediatric patients. Individuals with underlying congestive heart failure or bronchial asthma are also noted to be at increased risk for adverse outcomes.
Emergency-response statements (as written in official documents) Management requires symptomatic and supportive treatment. Specific procedures listed include administration of IV Atropine for bradycardia, IV Glucagon for persistent hypotension, and specialized interventions such as cardiac pacing or ventilatory support as needed.
When immediate medical help is required (label-derived phrasing only) Seek immediate medical attention or contact emergency services must be the immediate action for all suspected cases due to the potential for severe or life-threatening systemic collapse.

Overdose Classifications (High-Level)

Field Content
Severity classification (as defined in official documents) Overdose may result in severe or life-threatening complications, including cardiac arrest and acute cardiogenic shock.
Regulatory basis (EMA / FDA / etc.) Information derived from government-authorized Prescribing Information / Summary of Product Characteristics (SmPC) sections on overdose and acute toxicity.
Overdose-context constraints (as defined in official documents) No specific antidote is known.

Resulting Overdose Structure

Official Overdose Statements:

  • Overdose presents with serious systemic effects, including bradycardia, pronounced hypotension, and bronchospasm.
  • The most severe officially documented outcomes include cardiac arrest and acute congestive heart failure.
  • Seek immediate medical attention for all suspected cases of overdose.

Connection to the overall overdose profile Regulatory documents define the overdose profile for Iotim based on the potential for systemic beta-blockade, emphasizing the risk of acute cardiovascular and respiratory depression. This profile mandates that individuals must seek immediate medical attention when overdose is suspected, acknowledging the progression to life-threatening complications. The official structure focuses entirely on documented manifestations, specific life-threatening outcomes, and officially sanctioned emergency management procedures, explicitly noting the absence of a specific antidote.

Therapeutic Uses of Iotim

Main Uses of Iotim

Iotim is a topical ophthalmic solution primarily used to manage conditions characterized by elevated intraocular pressure. By lowering the pressure within the eye, the medication helps prevent damage to the optic nerve, which is essential for maintaining clear vision.

Chronic Open-Angle Glaucoma

The most common application for Iotim is the treatment of chronic open-angle glaucoma. This condition occurs when the eye's drainage system becomes less efficient over time, leading to a gradual increase in fluid pressure. If left unmanaged, this pressure can cause progressive loss of peripheral and central vision.

Ocular Hypertension

Iotim is also used to treat ocular hypertension, a state where the internal pressure of the eye is higher than the normal range, but the patient does not yet show signs of optic nerve damage or vision loss. Reducing pressure in these cases is a preventive measure to lower the risk of developing glaucoma.

Secondary Glaucoma

In certain instances, the medication may be used to manage secondary glaucoma, which results from other medical conditions, injuries, or the use of certain medications that interfere with the eye's natural fluid balance.

Benefits and Mechanism of Action

Reduction of Aqueous Humor Production

Iotim belongs to a class of medications known as beta-blockers. Its primary benefit is derived from its ability to decrease the production of aqueous humor, the clear fluid that fills the front part of the eye. By reducing the rate at which this fluid is produced, the overall pressure within the globe of the eye is lowered.

Preservation of Visual Function

The fundamental goal of treatment with Iotim is the long-term preservation of sight. High intraocular pressure is a major risk factor for glaucomatous nerve damage; by maintaining pressure at a stable and lower level, the medication helps to halt or slow the progression of vision impairment.

Consistency in Pressure Control

Iotim is valued for providing a sustained reduction in intraocular pressure throughout the day and night. This stability is crucial because fluctuations in eye pressure can contribute to the worsening of glaucomatous damage.

Regulatory References

  1. DailyMed (U.S. National Library of Medicine) drug information

Eligibility and Restrictions for Use

The eligibility for Iotim (Timolol ophthalmic solution) is strictly defined by official regulatory documentation, primarily due to the potential for systemic absorption of the beta-blocker component.

Absolute Contraindications

The medicine is prohibited for use in patients with severe cardiopulmonary conditions. These include Bronchial asthma or a history of asthma, and Severe Chronic Obstructive Pulmonary Disease (COPD). Use is also contraindicated in patients with Overt cardiac failure, Sinus bradycardia, and Second or Third-degree Atrioventricular (AV) block.

Population Eligibility and Restrictions

The medicine is approved for use in adults and children aged 2 years and older. However, safety and efficacy have been deemed not established for pediatric patients younger than 2 years. Use requires caution in patients with conditions such as Diabetes Mellitus (as the medicine may mask hypoglycemia symptoms), Myasthenia gravis, or less severe forms of COPD. For pregnancy, use is not recommended unless clearly necessary, and the drug is excreted in breast milk, mandating assessment before use during lactation.

What should I know about interactions with other medicines?

Iotim (Timolol maleate) is an ophthalmic solution with a documented interaction profile defined by its systemic absorption, leading to both pharmacodynamic and pharmacokinetic concerns found in regulatory labeling.

Pharmacodynamic Interactions

The profile is dominated by the risk of additive effects of beta-blockade. Co-administration with oral beta-adrenergic blocking agents (systemic beta-blockers) may result in an increased reduction of both systemic heart rate and intraocular pressure. Similarly, combining Iotim with oral or intravenous calcium antagonists (such as diltiazem or verapamil) is officially noted to cause additive cardiovascular depression, potentially resulting in marked bradycardia and hypotension. Catecholamine-depleting drugs (like reserpine) and certain antiarrhythmic agents also carry a risk of producing these same additive effects on cardiovascular parameters. For topical use, the co-administration of two beta-adrenergic blocking eye drops is not recommended according to regulatory restrictions.


Pharmacokinetic and Other Interactions

A documented pharmacokinetic interaction occurs with strong CYP2D6 Inhibitors, which include specific medicines like quinidine, fluoxetine, and paroxetine. Official labeling states that these inhibitors impede the metabolism of timolol, resulting in a significant increase in its plasma concentrations and a resulting potentiation of systemic beta-blockade. Separately, the profile notes that the medication can potentiate the risk of rebound hypertension following the withdrawal of agents such as clonidine.

Mechanism of Action

Key Receptor and Enzyme Modulation

Iotim's mechanism begins with its targeted interaction with specific receptor and enzyme systems. This initial action serves to modulate key biological targets, which alters signaling dynamics to dampen excessive pathway activity within fundamental regulatory systems. This initial interaction defines the mechanistic domain of the drug's action.

Intervention in Signal Transduction

Following its initial binding, Iotim operates within well-characterized signal transduction cascades. It exerts a targeted influence on the sequence of molecular events, often by initiating or suppressing the signaling sequences that lead to downstream effects. This intervention is relevant in states where specific mediators or transmitters are present in the signaling environment.

Regulation of Dysregulated Physiological Responses

The cumulative effect of Iotim's action on targets and pathways is the regulation of overactive or dysregulated physiological responses. The mechanism restricts the propagation of signals resulting from excessive mediator activity, influencing pathway stability within the affected central and/or peripheral pathways, which results in characteristic alterations to physiological responses.

Dosage and Administration Information

How to Use Iotim

Iotim (Timolol maleate ophthalmic solution) is administered with a focus on the route, precise dosing, and scheduling. This medication is intended for topical application onto the surface of the eye.


Official Administration Guidelines

Instruction Entity Detail
Route of administration Topical ophthalmic application onto the eye's surface.
Standard Dosing The typical starting regimen is one drop of the 0.25% solution in the affected eye(s), which may be increased to one drop of the 0.5% solution if the initial response is insufficient.
Frequency Pattern Applied twice daily (BID) initially. This frequency may be reduced to once daily (QD) for long-term maintenance of controlled intraocular pressure.
Course Duration The medication is for long-term pressure management, with therapeutic efficacy evaluated after approximately four weeks to allow for stabilization.

Procedural Context and Constraints

Administration involves instilling one drop only per dose. Specific procedural steps are used to facilitate proper delivery and limit systemic exposure, such as employing nasolacrimal occlusion or gentle eyelid closure for a few minutes after application. If other topical ophthalmic treatments are prescribed, they must be separated by an interval of at least 10 minutes to prevent interference.

For pediatric use, the lowest available concentration (e.g., 0.25% or less) is utilized, commencing with a once daily frequency and close monitoring following the initial application.

The simultaneous use of Iotim with any other topical beta-adrenergic blocking agent is not part of the standard usage protocol.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Iotim

Iotim is Timolol maleate ophthalmic solution, an agent that was studied for the management of fluid pressure within the eye. The understanding of this medicine is based on research that includes formal Randomized Controlled Trials (RCTs), comparisons against standard therapies, and long-term observational reports. This overview explains what the research has explored and what is known so far, without offering medical advice.


## Evidence for use in Elevated Eye Pressure (Ocular Hypertension)

Research exploring Iotim's application in elevated eye pressure, also known as ocular hypertension, has involved numerous short-term to intermediate-term Randomized Controlled Trials (RCTs). These studies were designed to compare the effects of the medicine against an inactive solution (placebo) or against other standard eye treatments. The primary focus of this research was the Intraocular Pressure (IOP), measured in units of millimeters of mercury (mmHg), which is a major factor studied in relation to eye damage.

In these trials, researchers monitored changes in IOP from the beginning of the study to specific time points, such as 3 or 6 months. Findings describe patterns observed in the studies where lower IOP measurements were recorded over the observed periods. These studies help show what has been observed so far regarding the medicine's effect on pressure levels. This body of evidence resulted in the medicine being used as a standard comparator in subsequent ophthalmic drug research.

However, the existing studies provide limited insight into whether these measured IOP changes directly translate into the stability of long-term visual function, such as stability of the visual field, for people with only ocular hypertension. Since most trials focus on the surrogate measure (IOP), there is limited information for very long-term outcomes when Iotim is used alone.


## Evidence for use in Chronic Open-Angle Glaucoma

Iotim was evaluated in the context of chronic open-angle glaucoma. In addition to RCTs, research in this area also includes long-term observational studies that monitor patients over extended periods. For this chronic condition, studies monitored sustained IOP control and also explored secondary outcomes related to functional stability, such as visual field tests and assessments of the optic nerve head.

Studies explored whether lower IOP measurements were maintained over repeated observations when using Iotim as a single agent or in combination products. Studies report how symptoms evolved in the observed populations, and the medicine's research history means its pressure measurements have been extensively reported and used as a comparator for regulatory review. Long-term research was conducted to understand patterns related to sustained management.


## What is Still Uncertain or Limited in the Research

The evidence base for Iotim provides context but not individual predictions. Several limitations have been noted in the broader research landscape:

  • Surrogate Endpoints: Most core efficacy research focuses primarily on Intraocular Pressure (IOP). While IOP is a critical risk factor, it is a surrogate endpoint, meaning the evidence mainly describes patterns related to pressure, not direct long-term stability of the optic nerve or sustained visual function.
  • Limited Information: As noted, there is limited information for long-term outcomes and functional preservation that extends well beyond the typical one-year study period. Research does not determine whether an individual will respond similarly to the group patterns described in the studies.

Frequently Asked Questions (FAQ)

Common questions about Iotim (FAQ)

Q: How quickly should Iotim start to have an effect?

Official product information indicates that the initial pressure-lowering effect typically begins approximately 20 minutes after the drops are applied. The maximum effect is typically reported to occur within one to two hours after administration.


Q: Can Iotim affect my mood or sleep patterns?

Studies and regulatory documents have noted that Iotim can, in rare instances, be associated with mood and sleep disturbances. These effects may include feeling down or depressed, or having difficulty sleeping (insomnia). Official labeling describes such effects as occurring in a low percentage of observed patients.


Q: Does Iotim need a special type of prescription?

Iotim is a prescription-only medicine (POM), but its active ingredient, Timolol maleate, is not classified as a controlled substance under the U.S. Controlled Substances Act (CSA). Therefore, it is not subject to the specialized tracking or prescription forms associated with federally controlled drugs.


Q: Why is Iotim sometimes taken in the morning and sometimes at night?

According to the official product information, the initial treatment often begins with a twice-daily (BID) dosing schedule. If satisfactory eye pressure control is achieved and maintained, the frequency may be reduced to a once-daily (QD) regimen based on pressure control patterns.


Q: Can Iotim affect my ability to drive or operate machinery?

Official documents caution that side effects such as dizziness, visual disturbances (e.g., blurred vision), or fatigue may affect a person's ability to drive or operate machinery safely.


Q: Are there known risks if I stop taking Iotim suddenly?

Because the eye drops are systemically absorbed, regulatory warnings associated with oral beta-blockers are relevant. In individuals with underlying heart conditions, the abrupt stoppage of systemic beta-blockers is known to potentially lead to a worsening of angina, heart attack, or irregular heart rhythms. It is important to know that sudden changes in therapy can carry risks, consistent with the warnings for this class of medicine.


Q: Is Iotim considered a first-line treatment for its approved condition?

The official documents clearly list the conditions Iotim is approved to treat, such as ocular hypertension and chronic open-angle glaucoma. However, regulatory documents typically do not officially specify or endorse a drug’s designation as 'first-line therapy' over other available treatments.


Q: What should I do if I miss a dose of Iotim?

The regulatory guidance on missed doses states that treatment should be continued with the next regularly scheduled dose. It is specifically advised that a double dose should not be administered to make up for a dose that was missed.


Q: Does Iotim cause weight gain or weight loss?

Official reports indicate that weight gain and weight loss have been observed in patients using the ophthalmic solution.


Q: Are there specific vitamins or supplements that interact with Iotim?

Official information advises that the product may interact with certain multivitamins that contain minerals. For safe use, it is generally recommended to separate the administration of these supplements and Iotim by at least two hours. It is important to disclose all products, including vitamins and herbs, to the prescribing healthcare provider.


Q: Is it okay to use Iotim with common pain relievers like ibuprofen?

Regulatory documents indicate that Nonsteroidal Anti-inflammatory Drugs (NSAIDs), which include common pain relievers like ibuprofen, may reduce the blood pressure-lowering effect of beta-blocking agents. For this reason, official information advises that patients taking both Iotim and an NSAID should be carefully observed.


Q: Is Iotim safe to use if I have kidney problems?

Because Iotim's active component is primarily excreted by the kidneys, official labeling advises that caution is required when the medicine is used in patients with impaired renal function. In such cases, the need for dosage adjustment is typically assessed during treatment.


Q: Can older adults use Iotim, and is their use restricted in any way?

Official studies have not identified specific problems unique to the elderly (geriatric-specific problems) that would limit the usefulness of Iotim eye drops in this population. Therefore, no blanket restrictions are placed on use in older adults based solely on age.


Q: What happens if Iotim is taken with alcohol?

Regulatory information indicates that alcohol may have an additive effect with Iotim in lowering blood pressure. Combining the two is noted to increase the risk of symptoms related to low blood pressure, such as dizziness or fainting (syncope).


Q: Is Iotim a controlled substance?

The active ingredient in Iotim, Timolol maleate, is not classified as a controlled substance under the U.S. Controlled Substances Act (CSA). The product is designated as a prescription-only medicine.


Q: Are there any ongoing clinical trials for new uses of Iotim?

Publicly registered clinical trial databases show that ongoing research continues to examine Iotim's safety and effectiveness. These trials primarily focus on fixed-dose combinations with other eye drops or use Iotim as a standard comparative agent for ocular hypertension and glaucoma.


Q: Is Iotim known to cause any skin reactions or rashes?

While primarily an eye medication, the official adverse reaction list notes that skin rashes have been reported in association with the use of beta-adrenoreceptor blocking drugs, the class to which Iotim belongs.


Q: Are there known interactions between Iotim and herbal remedies?

The official advice for Iotim is that patients are generally advised to inform their healthcare providers about all medications used, which includes herbal remedies and other supplements. This is to ensure that the risk of unknown interactions can be assessed.


Q: What kind of monitoring or tests are needed while taking Iotim?

Monitoring typically includes checks on blood pressure and heart rate to observe for unwanted systemic effects, consistent with regulatory guidance.


Q: Is it normal to feel a change in appetite while on Iotim?

Official regulatory documents list anorexia (which means loss of appetite) as one of the adverse reactions that has been reported in patients using this ophthalmic solution.


Q: Has Iotim been recalled or had any major safety alerts?

Official records from regulatory bodies have indicated instances of voluntary Class II recalls. These were typically due to non-medicinal issues, such as defects in the product's container, like caps getting lodged in the nozzle.


Q: How long has Iotim been available on the market?

The active ingredient in Iotim, Timolol maleate, has a long history. The first ophthalmic solution containing this ingredient was approved by the FDA prior to January 1, 1982, establishing it as a well-known agent in eye pressure management.


Q: What if I experience side effects that aren't listed on the package insert?

Official regulatory sources provide a pathway for patients and healthcare providers to report any suspected adverse reactions, such as the FDA’s MedWatch program.


Q: Can I travel internationally with Iotim?

General regulatory advice for traveling with prescription medication suggests keeping the product in its original container with a valid prescription or doctor's note. It is also typically recommended to limit the quantity carried to what is reasonably needed for personal use during the trip.


Q: Is it true that Iotim can only be prescribed by a specialist?

While Iotim is used for conditions like glaucoma and ocular hypertension, official patient information often indicates that eye drops for these conditions are typically prescribed by an optometrist or ophthalmologist, who are specialists in eye care.

How should Iotim be stored and disposed of?

Iotim (timolol maleate ophthalmic solution) must be stored and handled according to its official labeled requirements to ensure stability and sterility.

Storage Conditions

Constraint Requirement (Regulatory Basis)
Temperature Store at Controlled Room Temperature, typically 15 C to 25 C (59 F to 77 F).
Handling Protect the solution from freezing and excessive heat; keep the container tightly closed and stored upright.
Protection The product must be protected from light.
Child Safety The medicine must be kept out of the reach and sight of children.

Stability and Disposal

Constraint Requirement (Regulatory Basis)
In-Use Stability Discard the multi-dose container exactly 28 days (one month) after first opening.
Disposal Dispose of any unused or expired solution in accordance with local, regional, or national regulations for medicinal waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Iotim found in:

A-Z Index: